vatalanib has been researched along with Acute Myelogenous Leukemia in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP | 1 |
| Barbarroja, N; Carretero, RM; López-Pedrera, C; Lopez-Sanchez, LM; Luque, MJ; Rodriguez-Ariza, A; Torres, A; Torres, LA; Valverde-Estepa, A; Velasco, F | 1 |
| de Bont, ES; Kampen, KR; Kamps, WA; Meeuwsen-de Boer, T; Schuringa, JJ; Ter Elst, A; Weidenaar, AC | 1 |
| Bouma-ter Steege, JC; de Bont, ES; de Jonge, HJ; Douwes, J; Fidler, V; Hählen, K; Kamps, WA; Meeuwsen-de Boer, T; ter Elst, A; Weidenaar, AC | 1 |
4 other study(ies) available for vatalanib and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
The target landscape of clinical kinase drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays | 2017 |
Additive effect of PTK787/ZK 222584, a potent inhibitor of VEGFR phosphorylation, with Idarubicin in the treatment of acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Drug Synergism; fms-Like Tyrosine Kinase 3; Humans; Idarubicin; Leukemia, Myeloid, Acute; Neovascularization, Pathologic; Phthalazines; Pyridines; Receptors, Vascular Endothelial Growth Factor; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A | 2009 |
Impaired long-term expansion and self-renewal potential of pediatric acute myeloid leukemia-initiating cells by PTK787/ZK 222584.
Topics: Antibodies, Monoclonal, Humanized; Bevacizumab; Cell Growth Processes; Cell Line, Tumor; Child; Child, Preschool; Female; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Male; Phosphorylation; Phthalazines; Protein Kinase Inhibitors; Pyridines; Recurrence; Survival Analysis; Transduction, Genetic; Vascular Endothelial Growth Factor A | 2013 |
Addition of PTK787/ZK 222584 can lower the dosage of amsacrine to achieve equal amounts of acute myeloid leukemia cell death.
Topics: Amsacrine; Antineoplastic Agents; Cell Death; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Flow Cytometry; Humans; Leukemia, Myeloid, Acute; Phthalazines; Protein Kinase Inhibitors; Pyridines; Receptors, Vascular Endothelial Growth Factor; Reverse Transcriptase Polymerase Chain Reaction; RNA, Neoplasm | 2008 |